Copyright and Licensing
All content published in GEN Protocols is made freely and permanently available online upon publication without access or subscription charges, embargo periods, or user registration. Upon submitting a protocol for publication, author(s) agree to an Open Access Licensing Agreement. Authors of protocols published in GEN Protocols will be the copyright holders, and a Creative Commons (CC) BY license will be applied.
For authors who are US government employees or are prevented from being copyright holders for similar reasons, GEN Protocols can accommodate non-standard copyright. Please contact email@example.com for more details.
Publishing a protocol in GEN Protocols does not preclude publication of the material in another journal, but authors are advised to check relevant journal policies before submitting. GEN Protocols submissions based on methods published as part of other published articles should not violate journal copyright.
Protocols are not peer-reviewed. Upon submission, protocols are assessed by an editor for suitability in GEN Protocols. Protocols considered for inclusion in GEN Protocols must include a novel approach or an enhancement over an existing protocol. Contributors should only submit protocols that have worked for them and be prepared to respond to queries from individuals who are unable to replicate the protocol. We strongly urge contributors to include pilot data in the submission obtained through the protocol. Following the assessment, the editor will determine if the protocol will be published, requires revision, or is unacceptable for publication.
Authors are responsible for ensuring they have complied with all relevant ethical regulations and declarations of consent if the protocol involves human participants. If the protocol uses animal or human subjects, authors must include guidance that all experiments must be approved by the appropriate institutional review board and that human subjects provide informed consent.
GEN Protocols is committed to maintaining the integrity of the scientific process by upholding the highest standards for all published content. All submissions will be processed through plagiarism detection software prior to assessment. Plagiarized manuscripts will be rejected immediately.
By submitting a protocol to GEN Protocols, the author confirms he/she/they hold all necessary copyright and licensing required in order to publish his/her/their work in GEN Protocols.
When submitting copyrighted material, author(s) must obtain permission from the original publisher. The publication from which the material is taken must be listed in the reference list and all permissions must be supplied at the time of submission. Authors are responsible for any fees that may be incurred by securing permission to reproduce or adapt material from other published sources.
GEN Protocols allows for protocols that were previously deposited on preprint servers to be submitted to GEN Protocols, with the proviso that the author updates any preprint versions with a link to the final version published by GEN Protocols. All submissions are subject to editorial assessment for suitability and allowing the submission of preprint content does not guarantee publication in GEN Protocols.
The author of a protocol that was previously deposited to a preprint server should include a disclosure statement indicating the name and website of the server and include the DOI number of the preprint if applicable.
Author Disclosure Statements
For all submission, GEN Protocols encourages the use of CRediT (Contribution Roles Taxonomy) to assign each contributor one of 14 roles as listed here.
An authorship disclosure statement containing the following information must be included with the submission:
Competing Interests. A competing interest exists when an individual (or the individual's institution) has financial or personal relationships that may inappropriately influence his actions. These competing interests may be potential or actual, financial or other.
Personal Financial Interests. Stocks or shares in a company that may gain or lose financially from publication of the article; consulting fees or other remuneration from an organization that may gain or lose financially from publication of the article; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of the article.
Funding. Research support by organizations that may gain or lose financially from publication of the article. This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.
Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of the article.
Other Competing Interests. Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgement.
GEN Protocols strongly advocates the sharing and archiving of the data and any other artifacts that define and support the results stated in a manuscript in a suitable public repository (in accordance with valid privacy, legal, and ethical guidelines). A data availability statement should be included with the protocol, describing the location of the data, with details on how it can be accessed as well as any licensing information. If the data is not publicly available or accessible, that information should also be provided.
Datasets should be cited in the reference list by Author (Year). Title. Publisher. Identifier/DOI.
Important: Please check with your funding agencies to ensure that are you following their data sharing polices. If your funding agency has additional requirements exceeding our policy, you must follow the requirements of your funder.
ApplicationA Fast and High Precision Influenza Vaccine Potency Assay
ApplicationStrategies for the Development of a High Throughput Octet® Bio-Layer Interferometry Method to Measure Pharmacokinetics of Monoclonal Antibodies in Preclinical Animal Models
ApplicationEffective Dead Cell Depletion using Microbubbles Delivers High Yield
ProtocolPreclinical Optimization and Safety Studies of a New Lentiviral Gene Therapy for p47phox-Deficient Chronic Granulomatous Disease
ProtocolHigh-Throughput In Vitro, Ex Vivo, and In Vivo Screen of Adeno-Associated Virus Vectors Based on Physical and Functional Transduction
ProtocolEffective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells